24 results about "AORTIC VALVULAR STENOSIS" patented technology

A computer-implemented method for grading of Aortic Stenosis severity performed by an automated workflow engine executed by at least one processor includes receiving, from a memory, a plurality of echocardiogram images a heart. The plurality of echocardiogram (echo) images according to 2D images and Doppler modality images. The 2D images are classified by view type, and the Doppler modality images are classified by region. The regions of interest in the 2D images are segmented to produce segmented 2D images. The Doppler modality images are segmented to generate waveform traces to produce segmented Doppler modality images. The segmented images are used to calculate measurements of cardiac features of the heart. A conclusion of Aortic Stenosis severity is generated by comparing the calculated measurements to cardiac guidelines. A report is then output showing the calculated measurements of the cardiac features that fall within or outside of the cardiac guidelines.

Methods and systems for automatic classification, detection, assessment, and / or diagnosis of a pathology in a subject determine presence or absence, and / or a severity of various pathologies in a subject, for example, presence, absences, and / or severity of aortic stenosis in a heart of a subject.

The invention mainly aims to provide a heart valve anomaly analysis method based on deep learning, and the abnormal condition of a heart valve, especially the severity of aortic stenosis, is accurately detected through automatic image processing and stenosis rate calculation. The method can reduce errors of manual operation and improve the diagnosis efficiency of heart valve diseases.

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with the expression of the LPA gene or inhibit its expression, preferably for use as a treatment / treatment, prevention or reduction of the risk of (an individual) suffering from cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome associated with elevated levels of Lp(a) particles.

The invention relates to application of gamma-tocotrienol in treating cardiac fibrosis, in particular to cardiac fibrosis caused by aortic stenosis and / or myocardial ischemia reperfusion. The administration of the gamma-tocotrienol can significantly relieve cardiac inflammation caused by aortic stenosis and / or myocardial ischemia reperfusion, and effectively inhibit cardiac fibrosis.

The present invention provides a valve stent and a usage method thereof for bicuspid aortic valve stenosis, comprising an ascending aorta contact area, a connecting body, a valve support area and a valve prosthesis suture part; the ascending aorta contact area is in an annular shape, a honeycomb-like structure formed by arranging and connecting a plurality of regular hexagons; the valve support area is in an elliptical annular shape, a grid structure formed by arranging and connecting a plurality of rhombuses. The present invention enhances the radial stiffness of the stent, thereby improving its radial support capacity; the valve support area is designed as an elliptical ring structure, and when implanting the artificial heart valve stent, the long-axis implantation angle of the valve stent is kept perpendicular to the long axis of the valve annulus, and by using the mutual coupling effect between the two, the cross-sectional shape of the expanded valve stent is finally circular, which improves the problem of poor expansion during the implantation of the valve stent and the elliptization after the valve stent is implanted, thereby reducing the occurrence of paravalvular leakage, with uniform stress and extended service life.

Provided herein is a method of stratifying the risk of cardiovascular disease development and progression using multi-modal video-based modeling. The method includes providing a training set including a plurality of imaging sequences from normal subjects and subjects with the condition of interest, such as aortic stenosis, and training a machine-learning model to detect phenotypes associated with distinct severity levels of the condition and predict the risk of disease development or progression. Also provided herein is a computer-implemented method of detecting a heart condition using the machine learning model across distinct imaging modalities and an apparatus for executing the computer-implemented method.

A device for generating information indicating cardiac abnormalities such as aortic stenosis includes a signal interface (101) for receiving signals measured using a motion sensor that indicates the movement of the heart and has mechanical contact with the individual's chest. The device includes a processing system (102) configured to form descriptor values ​​that describe the intensity of the highest peak repeating in the heart rate in the signal relative to the intensity of other parts outside the highest peak of the signal. The processing system is configured to set a display signal output by the device to indicate the presence of a cardiac abnormality when the descriptor value is outside a predetermined range of values ​​corresponding to a healthy case.

This invention relates to a method and apparatus for quantitatively assessing left ventricular outflow tract obstruction and aortic stenosis. The method includes acquiring the outflow tract pressure gradient and cardiac output; determining the relationship between cardiac output and outflow tract pressure gradient using Bernoulli's equation; calculating the cardiac obstruction coefficient based on the equation; the cardiac obstruction coefficient includes the cardiac obstruction coefficient from the left ventricular cavity to the outflow tract segment and the cardiac obstruction coefficient from the outflow tract to the ascending aorta; and assessing the patient's obstruction status based on the cardiac obstruction coefficient. The cardiac obstruction coefficient calculated by this invention is mainly determined by the morphology of the patient's blood flow cavity and is not affected by cardiac output, thus providing a more accurate description of the patient's obstruction status. This helps physicians make more accurate clinical judgments.

The utility model discloses a balloon of a transcatheter aortic valve conveying system, which comprises a balloon, and after the balloon is filled, the middle of the balloon is of a bee waist-shaped structure. Compared with the prior art, the middle of the balloon is arranged to be of the wasp-waist-shaped structure, the periphery of the wasp-waist-shaped structure covers the edges of the valve support and the calcified valve, and on one hand, the phenomenon of perivalvular leakage is reduced; and on the other hand, the balloon can be better positioned at a natural valve through the bee waist-shaped structure, and is not easy to fall off from an aortic stenosis part.

The present disclosure provides a method for providing information on severity of aortic stenosis implemented by a processor, the method including receiving a cardiac ultrasound image of a subject, extracting features from the received cardiac ultrasound image using a prediction model trained to predict the severity of the aortic stenosis by inputting the cardiac ultrasound image, and determining the severity of the aortic stenosis for the subject based on the extracted features using the prediction model, and provides a device using the same.

Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve—a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.

Methods and systems for automatic classification, detection, assessment, and / or diagnosis of a pathology in a subject determine presence or absence, and / or a severity of various pathologies in a subject, for example, presence, absences, and / or severity of aortic stenosis in a heart of a subject.

An apparatus for producing information indicative of cardiac abnormality, for example aortic stenosis, comprises a signal interface (101) for receiving a signal indicative of cardiac motion and measured with a motion sensor having a mechanical contact with a chest of an individual The apparatus comprises a processing system (102) configured to form a descriptor value describing strength of highest peaks repeating at a heartbeat rate in the signal relative to strength of other portions of the signal outside the highest peaks. The processing system is configured to set an indicator signal outputted by the apparatus to express presence of cardiac abnormality in response to a situation in which the descriptor value is outside a predetermined value-range corresponding to healthy cases.

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.

The invention relates to the technical field of biological medicines, in particular to application of a COX6A2 activator in preparation of heart failure related medicines. According to the application disclosed by the invention, by activating the COX6A2 and improving the expression level of the COX6A2, pathological cardiac hypertrophy caused by pressure overload (such as hypertension and aortic stenosis) can be prevented or treated, and the pathological process of heart failure (especially ejection fraction retention type heart failure and HFpEF) can be delayed or reversed; and myocardial mitochondrial dysfunction related diseases (such as diabetic cardiomyopathy and ischemic heart disease) can be improved.

A system for producing information indicative of cardiac abnormality, for example aortic stenosis, comprises a signal interface (101) for receiving a signal indicative of cardiac motion and generated by a motion sensor system (103) having a mechanical contact with a chest of an individual The system comprises a processing system (102) configured to extract, from the motion signal, samples each having a temporal length of one or more heart-beat periods so that a temporal phase of heart-beat related features with respect to a beginning of the sample is same within each of the samples, compute an integral transform of each of the samples to map each of the samples to basis-functions of the integral transform, and classify the samples to correspond either a healthy case or a cardiac abnormality based on coefficients resulting in the integral transform of each of the samples.

The present disclosure relates generally to the treatment of subjects having aortic stenosis, or at risk of developing aortic stenosis, by administering an Alkaline Phosphatase (ALPL) inhibitor to the subject.

A molecular marker for diagnosing, prognosis, evaluating, and treating cardiac fibrosis and belongs to the technical field of biomedicine. The present disclosure provides a molecular marker capable of diagnosing cardiac fibrosis, assessing the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular disease with cardiac fibrosis, or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises hepatocyte growth factor. It has been found that HGF is significantly elevated in the plasma of patients with cardiac fibrosis and also considerably elevated in patients with aortic stenosis before surgery. Therefore, HGF can be used to diagnose cardiac fibrosis and evaluate its severity.

To provide methods and materials involved in treating cardiovascular conditions such as calcific aortic valve stenosis.SOLUTION: For example, methods and materials for using sGC agonists or a combination of sGC agonists and PDE5A inhibitors to reduce calcification of heart valves and / or vessels or to slow progression of aortic sclerosis to calcific aortic valve stenosis are provided.SELECTED DRAWING: Figure 1A

The present disclosure relates generally to the treatment of subjects having aortic stenosis, or at risk of developing aortic stenosis, by administering an Alkaline Phosphatase (ALPL) inhibitor to the subject.

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with the expression of the LPA gene or inhibit its expression for use in the treatment, prevention or reduction of the risk of suffering from cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome associated with elevated levels of Lp(a)-containing particles.

The invention relates to the therapeutic inhibition of LPA gene expression, and in particular to effective doses and dosage regimes for the therapeutic use of the SLN360 molecule, in the prophylaxis or treatment of conditions associated with elevated levels of Lp(a). Such conditions include stroke, atherosclerosis, thrombosis, and cardiovascular diseases such as coronary heart disease and aortic stenosis.

An apparatus for producing information indicative of cardiac abnormality, for example aortic stenosis, comprises a signal interface (101) for receiving a first signal indicative of cardiac acceleration and measured with an accelerometer having a mechanical contact with a chest of an individual and a second signal indicative of cardiac rotation and measured with a gyroscope having a mechanical contact with the chest of the individual The apparatus comprises a processing system (102) configured to form a first descriptor value expressing a property of the first signal and a second descriptor value expressing the same property of the second signal, and to set an indicator signal outputted by the apparatus to express presence of cardiac abnormality in response to a situation in which the first descriptor value and the second descriptor value with respect to each other are indicative of the cardiac abnormality.